Background {#Sec1}
==========

Diabetes mellitus (DM) is responsible for high global mortality rates and high disability burden \[[@CR1]\] and is a major risk factor for cardiovascular disease. The presence of both DM and cardiovascular disease (CVD) increases the risk of death \[[@CR2]--[@CR5]\]. The global prevalence of DM has almost doubled in the adult population since 1980 (4.7 to 8.5%). In 2012, 1.5 million people died by DM. High blood glucose levels caused an additional 2.2 million deaths due to increased cardiovascular risk and other diseases. The percentage of deaths attributable to high blood glucose or diabetes that occurs prior to age 70 is higher in low- and middle-income countries (LMICs) than in high-income countries (HICs) \[[@CR6]\].

In the world, 80% of cases of noncommunicable diseases (NCDs) occur in LMICs \[[@CR7]\]. Most countries in Latin America, at least during the last 50 years, have experienced an epidemiological transition within a "prolonged polarized model", presenting complex transformation of their conditions of health, with the existence of a double burden of disease or epidemiological superposition \[[@CR8], [@CR9]\]. In Colombia, DM is among the first 10 causes of general mortality and within the first 20 causes of years of healthy life lost (YHLL) in a population ≥ 45 years \[[@CR10]\]. According to several studies in population of high-income countries (HIC), patients with Type 2 DM have a considerably higher risk of cardiovascular morbidity and mortality. However, it is not clear if the magnitude of this association can be widespread in other populations. This has been attributed to older age and a higher prevalence of cardiovascular risk factors among people with diabetes \[[@CR11]\]. In observational studies of cases and controls that included participants from Latin America, including Colombia, an association between DM and AMI has been reported. In the INTERHEART study, a significant association between DM and AMI (Odds Ratio (OR) 2.59, 95% Confidence Interval (CI) 2.09--3.22) and a population risk attributable to DM of 17.2% was reported \[[@CR12]\]. In the INTERSTROKE study, a significant association between DM and stroke (Relative Risk (RR) 1.36, 95% CI 1.10--1.68) and a population risk attributable to DM of 5% was reported \[[@CR13]\]. In randomized clinical trials such as the NAVIGATOR study, Latin American participants with glucose intolerance had an increased risk of cardiovascular death (Hazard Risk (HR) 2.68, 95% CI 1.82--3.96) and composite cardiovascular outcome (HR 1.48, 95% CI 1.15--1.92) \[[@CR14]\]. Traditional multivariate risk adjustment models may be limited by residual biases and questioned the reliability and when the data are recorded in the context of a clinical trial, they may not reflect the real characteristics of the population by the specified selection criteria. In addition, there may be variation in the management plans of cardiovascular risk programs even within a given region. Matching propensity scores allow balancing the covariates of baselines measured in the cohorts to obtain more robust results \[[@CR15]\].

The objective of this study was to examine the association between Type 2 DM with first cardiovascular event in a cohort of type 2 DM Colombian Caribbean poor population with no previous records of cardiovascular events compared with a paired matched cohort of patients with no presence of DM.

Methods {#Sec2}
=======

Study population and cohort {#Sec3}
---------------------------

In 2015 Colombia had 48.2 million people. 10.3 million of them live in the Caribbean Region. For this study, patients from a Colombian public health insurance company were selected. By 2015, it had 1.2 million insured people from poor households of the Colombian Caribbean region (11.6% of the population in the Caribbean region). 49% are male, sex ratio 1:1 and 54% are under 30 years old, which indicates a representative and very similar population structure to the Colombian Caribbean region \[[@CR16]\].

The insurance company have a cardiovascular risk management program, which performs screening of cardiovascular risk factors and the detection of cardiovascular events in the affiliated population. Screened patients who reported presence of risk factors were enrolled in the cardiovascular risk management program, which carry out a plan of follow-up activities according to the stratification of cardiovascular risk from the Framingham Risk Score.

Sociodemographic and clinical characteristics of enrolled patients from the program are registered in a private platform of the health insurance company. For the current investigation, we had access to the individual records of service provision registered between July 2014 and December 2015. In 2015, there were 64,668 (66.5% women) patients enrolled in the program. More than 90% of them were over 45 years old.

History of type 2 diabetes mellitus {#Sec4}
-----------------------------------

Patients with type 2 DM were identified through at least once of the following characteristics: having ICD − 10 diagnosis code, having a personal reported history of DM, having glycosylated hemoglobin levels\> 6.5% at least once in records and those under anti-diabetic treatment. From the identified patients, we excluded the ones with a personal history of previous cardiovascular events, and diabetics younger than 30 years under treatment with insulin and without oral anti-diabetics.

Study outcomes {#Sec5}
--------------

For the current analysis, the main outcome were first CVD events related endpoints: such as acute myocardial infarction, angina pectoris, acute stroke, mortality due to CVD, and hospitalization due to CVD during 1.5 years of follow-up (12,7 average months of follow-up and range, 1--18 months). CVD events were confirmed by ICD-10 diagnosis CVD events related endpoints from the cardiovascular risk management program hospitalizations database. Follow-up was censored with presence of cardiovascular events, death, or the end of the study, whichever occurred first.

For the current investigation, we had access to hospitalizations records between July 2014 and December 2015, which were previously verified by the internal auditors of the health insurance company. The exact date of death of the patients was not available. So the date of hospitalization due to cardiovascular events or any other date was considered and imputed as the date of death in patients registered as "deceased" in the database of the program whose date of hospitalization was after the date of the last monitoring control observed. In the patients registered as "deceased" who did not have a record of hospitalizations, the median date between the date of the last control observed and the expected date of the next control was considered as the date of death.

Covariates and propensity score matching {#Sec6}
----------------------------------------

We used the propensity score method and performed 1:1 nearest-neighbor matching without replacement due to imbalances in baseline characteristics between patients with and without Type 2 DM. We used a non-parsimonious multivariable logistic regression model to estimate propensity scores for Type 2 DM. In the model, Type 2 DM was the dependent variable and clinically relevant baseline characteristics were used as covariates. Then a *P* value of less 0.20 was defined for selecting variables for entry into the final model. Selected variables were as follows: age, sex, smoking, physical activity, hypertension, obesity, hyperlipidemia, chronic kidney disease (CKD), hypertension control, Angiotensin-Converting Enzyme Inhibitors (ACEI)-Angiotensin-Receptor Blocker (ARB), calcium-antagonists, statins, antiplatelet and number of anti-hypertensive drugs. By using these covariates, a propensity score was calculated for each patient. Finally, each patient who underwent Type 2 DM was matched to one patient who underwent no Type 2 DM with the closest propensity score. The maximum difference of propensity score for a match was less than 0.03. To ensure that the post-match comparisons between patients with and without diabetes were not affected by the small sample size of the matched cohort, we assembled a pre-match cohort of the same sample size as that of the matched cohort. This was done by first identifying the 18,449 patients with diabetes in the matched cohort. Then, we identified a random sample of 18,449 patients without diabetes from the entire pre-match sample of 36,898 patients without diabetes. Finally, we linked these two data sets, thus assembling a cohort of 18,449 pairs of patients with and without diabetes.

Statistical analysis {#Sec7}
--------------------

Baseline characteristics were presented through absolute and relative frequencies and means with standard deviations. We used *Pearson Chi-square* and *Wilcoxon Rank-Sum* tests for the pre-match comparison and *paired sample t-test* for the post-match comparisons of baseline covariates between patients with and without DM. The *Kaplan--Meier* curves were constructed for the cardiovascular events related endpoints and matched *Cox-regression* analysis to estimate associations of a history of Type 2 DM with cardiovascular outcomes during 1.5 years of follow-up. Log-minus-log scale risk plots were used to check proportional hazards assumptions. A formal sensitivity analysis using *The Breslow-Day and Tarone Homogeneity tests* was conducted. All statistical analyses were conducted using the Stata version 14.2 software (StataCorp, College Station, TX) and R version 3.4.3 (R Core Team, R Foundation for Statistical Computing). *P* value \< 0.05 was considered statistically significant for all tests.

Results {#Sec8}
=======

Baseline characteristics before propensity matching {#Sec9}
---------------------------------------------------

All 56,351 patients included in the study are from a low socioeconomic level. We could not access to information on educational level, civil status and other sociodemographic characteristics due to restrictions of the insurance company. After identification, 19,368 (34.4%) patients were identified through the Type 2 DM records as follow; 14,131 (73%) by the ICD-10 diagnosis of DM, 323 (1.7%) by a personal history of DM, 2334 (12.1%) by glycosylated hemoglobin levels\> 6.5% at least once and 2579 (13.3%) by the reported treatment with anti-diabetic medicines. Patients were significantly younger in the personal history of Type 2 DM (−) group compared with the personal history of Type 2 DM (+) group (63.6 ± 13.1 years old versus 65.6 ± 13.6 years old); the number of anti-hypertensive drugs in the personal history of Type 2 DM (+) group is lower compared with the personal history of Type 2 DM (−) group (0.69 ± 0.45 versus 0.72 ± 0.44). 36.7% achieved good metabolic control (glycosylated hemoglobin \< 7%).

The incidence rate of first cardiovascular event in \> 65 years old was 22.9/1000 person -- year (95% CI 21.0--25.0) (Incidence Rate Ratio (IRR) 3.15 when ≥ 65 years old group was compared with \< 65 years old group, 95% IC 2.65--3.75). The incidence rate of first acute myocardial infarction or angina pectoris event (AMI) in \> 65 years old was 13.9/1000 person -- year (95% CI 12.4--15.5) (IRR) 2.63 when ≥ 65 years old group was compared with \< 65 years old group, 95% IC 2.14--3.26). The incidence rate stroke in \> 65 years old was 9.31/1000 person -- year (95% CI 8.13--10.67) (IRR 4.68 when ≥ 65 years old group was compared with \< 65 years old group, 95% IC 3.41--6.53).

There were several parameters of baseline characteristics statistically higher in the family history of DM (+) group, including the percentage of female gender (68.07% vs. 65.33%), hypertension control (90.74% vs. 89.28%), use of antiplatelet (41.59% vs. 37.12%) and use of statins (52.05% vs. 44.54%). The incidence rate of first cardiovascular event in man was 20.9/1000 person -- year (95% CI 18.6--23.5) (IRR 1.49 when men's group was compared with women's group, 95% IC 1.29--1.72). The incidence rate of AMI in man was 14.2/1000 person -- year (95% CI 13.3--16.3) (IRR 1.66 when men's group was compared with women's group, 95% IC 1.38--1.99). The incidence rate of stroke in man was 6.95/1000 person -- year (95% CI 5.67--8.51) (IRR 1.23 when men's group was compared with women's group, 95% IC 0.96--1.67).

Among 19,368 subjects with a personal history of Type 2 DM (+) group, 667 (3.4%) subjects had a first cardiovascular event before propensity score matching. Among 18,449 subjects with a personal history of Type 2 DM (+) group, 650 (3.5%) subjects had a first cardiovascular event after propensity score matching. The incidence rate of first cardiovascular event was 22.2/1000 person -- year (95% CI 19.9--24.7) (IRR 1.86 when Type 2 DM (+) group was compared with Type 2 DM (−) group, 95% IC 1.65--2.15). The incidence rate of AMI was 14.4/1000 person -- year (95% CI 12.6--16.4) (IRR 2.00 when Type 2 DM (+) group was compared with Type 2 DM (−) group, 95% IC 1.67--2.39). The incidence rate of stroke was 8.05/1000 person -- year (95% CI 6.73--9.63) (IRR 1.66 when Type 2 DM (+) group was compared with Type 2 DM (−) group, 95% IC 1.31--2.11).

Among 19,368 subjects with a personal history of Type 2 DM (+) group, 3418 (17.4%) subjects were under treatment of human or analogous insulin. Of these, 213 (6.2%) subjects had a first cardiovascular event before propensity score matching. The incidence rate of first cardiovascular event was 41.01/1000 person -- year (95% CI 34.08--49.36) (IRR 2.05 when Type 2 DM (+) group under human or analogous insulin treatment was compared with Type 2 DM (+) group without treatment with human or analogous insulin, 95% IC 1.73--2.42). The incidence rate AMI was 27.4/1000 person -- year (95% CI 21.90--34.44) (IRR 2.03 when Type 2 DM (+) group under human or analogous insulin treatment was compared with Type 2 DM (+) group without treatment with human or analogous insulin, 95% IC 1.65--2.50). The incidence rate of stroke was 14.64/1000 person -- year (95% CI 10.74--19.97) (IRR 2.13 when Type 2 DM (+) group under human or analogous insulin treatment was compared with Type 2 DM (+) group without treatment with human or analogous insulin, 95% IC 1.60--2.80).

To explore this imbalance, we illustrate a histogram of propensity score distribution for groups with and without personal history Type 2 DM before Fig. [1](#Fig1){ref-type="fig"} (a) and after Fig. [1](#Fig1){ref-type="fig"} (b) propensity matching.Fig. 1Propensity score distribution before (**a**-No Matchet cohort) and after (**b**-Matchet cohort) propensity score matching

Baseline characteristics after Propensity matching {#Sec10}
--------------------------------------------------

According to the propensity score matching 1:1 shown in Table [1](#Tab1){ref-type="table"}, 18,446 patients in the personal history of Type 2 DM (+) group were matched with 18,446 in the personal history of Type 2 DM (−) group. All absolute standardized differences after the match for all covariates were \< 5% and showed sufficient overlap in the estimated propensity scores. The characteristics of propensity score-matched patients with (*n* = 18,449) and without (*n* = 18,449) Type 2 DM are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline Characteristics by history of Type 2 DM before and after propensity Matching cohortBefore propensity matching (*N* = 56,351)After propensity matching (*N* = 36,898)n(%) / mean(±sd)No T2DMT2DMPNo T2DMT2DMPWomen24,49513,299\< 0.00112,74112,6440.27666.2368.6669.0668.53Age65.50 (+ − 13.66)63.24 (+ − 13.08)\< 0.00163.7 (+ − 13.5)63.8 (+ − 13.0)0.7186Hypertension36,44417,998\< 0.00117,91517,9350.53198.5492.9397.1197.21Dyslipidemia31,32316,685\< 0.00115,95615,9830.68084.786.1586.4986.63Obesity14,3239700\< 0.001927893150.70038.7350.0850.2950.49Controlled Hypertension33,09617,582\< 0.00116,65216,7020.37789.4990.7890.2690.53CKD54403184\< 0.001304030340.93314.7116.4416.4816.45Number of antihypertensive drugs0.72 (+ − 0.44)0.67 (+ − 0.46)\< 0.0011.81(+ − 1.66)1.82(+ − 1.8)0.227ACEI-ARB24,21812,126\< 0.00112,07512,0720.97465.4862.6165.4565.43Antiplatelet12,9577492\< 0.001724273470.26435.0438.6839.2539.82Calcium Antagonists99435878\< 0.001577658170.64626.8930.3531.3131.53Statins15,6249672\< 0.001932393820.53942.2549.9450.5350.85Insulin03418\< 0.00103222\< 0.001017.65017.46Human Insulin01604\< 0.00101497\< 0.00108.2808.11Analogous Insulin02503\< 0.00102375\< 0.001012.92012.87Sulfonylureas05852\< 0.00105548\< 0.001030.21030.07Metformin08430\< 0.00107950\< 0.0010043.53043.09DPP4-I0677\< 0.0010648\< 0.00103.503.51GLP1 receptor agonists088\< 0.001085\< 0.00100.4500.46

Type 2 DM and first CVD Events {#Sec11}
------------------------------

In the group with and without a personal history of DM type 2, the first CVD event occurred in 650 (3.5%) and 403 (2.1%) patients, respectively (incidence rate 22.1/1000 person -- year (95% IC 19.8--24.6) and HR 1.69; 95% CI 1.43--2.00; Fig. [2](#Fig2){ref-type="fig"}). In the subgroups analysis, the homogeneous association that a personal history of DM type 2 had with the first CVD event in a broad spectrum of patients was estimated (Table [2](#Tab2){ref-type="table"}).Fig. 2Kaplan-Meier plots for first cardiovascular event in T2DM matching cohortTable 2Association of a history of Type 2 DM and first event cardiovascularT2DM (event/N)EffectBreslow-Day homogeneity testNoYesORIC95Sex Women207/12741370/126441.8251.5322.1760.4520.056 Men196/5708280/58051.4251.1781.7250.298Age  \< 65 years136/9807196/97191.4641.1681.8380.3170.238  \> =65 years267/8642454/87301.7211.4712.0140.419CKD No308/15409503/154151.6541.4291.9140.3950.760 Yes95/3040147/30341.5781.2052.0760.366Controlled Hypertension No47/179776/17471.6931.1542.5050.4090.847 Yes356/16652574/167021.6291.4221.8670.386Dyslipidemia No18/249333/24661.8651.0163.5260.4640.647 Yes385/15956617/159831.6241.4241.8520.384Obesity No242/9171385/91341.6241.3741.9180.3840.873 Yes161/9278265/93151.6581.3542.0340.397Hypertension No1/5340/5140.2095^a^ Yes402/17915650/179351.6381.4411.8620.390ACEI-ARB No37/637447/63771.2720.8082.0150.2140.225 Yes366/12075603/120721.6821.4701.9240.405Calcium Antagonist No169/12673269/126321.6101.3201.9640.3790.815 Yes234/5776381/58171.6601.4001.9690.398Statins No61/912692/90671.5231.0892.1430.3440.632 Yes342/9323558/93821.6611.4441.9100.398Antiplatelet No95/11207144/111021.5371.1762.0160.3490.599 Yes308/7242506/73471.6651.4361.9310.399Number antihypertensive drugs  \< 249/906268/94211.3370.9121.9730.2520.172  \> =2354/9387582/90281.7581.5322.0180.431^a^ Tarone's homogeneity test

In the group with and without a personal history of DM type 2, the first acute myocardial infarction or angina pectoris event (AMI) occurred in 424 (2.3%) and 254 (1.3%) patients, respectively (incidence rate 14.4 person -year (95% CI 12.6--16.5); HR 1.79; 95% CI 1.45--2.20; *p* = 0.000; Fig. [2](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). In the group with and without a personal history of DM type 2, the first acute stroke event occurred in 234 (1.2%) and 153 (0.8%) patients, respectively (incidence rate 8,1 / 1000 person -- year (95% CI 6,7 - 9,6); HR 1.54; 95% CI 1.18--2.02; *p* = 0.001; Fig. [2](#Fig2){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}).Table 3Association of a history of Type 2 DM and first event AMIT2DM (event/N)EffectBreslow-Day homogeneity testNoYesORIC95Sex Women133/12741228/126441.7411.3972.1750.4260.636 Men133/5708228/58051.6131.2762.0470.380Age  \< 65 years100/9807144/97191.4601.1211.9060.3150.176  \> =65 years154/8642280/87301.8261.4912.2430.452CKD No198/15409330/154151.6811.4022.0150.4050.944 Yes56/304094/30341.7041.2062.4240.413Control HTA No31/179748/17471.6090.9982.6290.5850.385 Yes223/16652376/167021.6971.4312.0120.398Dyslipidemia No8/249319/24662.4121.0066.3790.4640.647 Yes246/15956405/159831.6601.4101.9550.384Obesity No146/9171246/91341.7111.3852.1190.4160.835 Yes108/9278178/93151.6541.2932.1240.395Hypertension No1/5340/5140.2026^a^ Yes253/17915424/179351.6901.4401.9840.408ACEI-ARB No22/637425/63771.1360.6142.1160.1200.159 Yes232/12075399/120721.7451.4762.0620.427Calcium Antagonist No120/12673191/126321.6061.2702.0380.3770.577 Yes134/5776233/58171.7571.4102.1960.431Statins No25/912655/90672.2221.3593.7230.5500.223 Yes229/9323369/93821.6261.3711.9290.385Antiplatelet No44/1120783/111021.9111.3092.8230.4770.442 Yes210/7242341/73471.6301.3631.9490.386Number antihypertensive drugs  \< 224/906234/94211.3640.7852.4060.2670.324  \> =2230/9387390/90281.7981.5182.1290.444^a^ Tarone's homogeneity testTable 4Association of a history of Type 2 DM and first event strokeT2DM (event/N)EffectBreslow-Day homogeneity testNoSiORIC95Sex Women78/12741145/126441.8831.4192.5150.4690.024 Men75/570889/58051.1690.8481.6150.145Age  \< 65 years37/980753/97191.4480.9332.2690.3090.769  \> =65 years116/8642181/87301.5561.2231.9860.357CKD No112/15409179/154151.6051.2592.0530.3770.474 Yes41/304055/30341.3500.8822.0820.260Control HTA No17/179729/17471.7670.9353.4400.4340.629 Yes136/16652205/167021.5091.2081.8900.337Dyslipidemia No10/249315/24661.5200.6373.7900.3420.980 Yes143/15956219/159831.5361.2371.9120.349Obesity No99/9171145/91341.4781.1351.9310.3230.617 Yes54/927889/93151.6481.1602.3570.393Hypertension No0/5340/5141^a^ Yes153/17915234/179351.5351.2451.8960.348ACEI-ARB No16/637422/63771.3760.6902.8040.2730.720 Yes137/12075212/120721.5581.2491.9480.358Calcium Antagonist No52/1267381/126321.5661.0912.2640.3620.886 Yes101/5776153/58171.5181.1691.9760.341Statins No36/912638/90671.0630.6551.7260.0590.080 Yes117/9323196/93821.6791.3262.1330.404Antiplatelet No52/1120763/111021.2240.8341.8040.1830.159 Yes101/7242171/73471.6851.3072.1810.406Number antihypertensive drugs  \< 226/906234/94211.2590.7332.1860.2060.340  \> =2127/9387200/90281.6521.3132.0840.395^a^ Tarone's homogeneity test

Type 2 DM and other outcomes {#Sec12}
----------------------------

Significant unadjusted associations were estimated between the personal history of DM type 2 and several outcomes among the pre-match cohort. Among the 36,898 balanced cohorts, type 2 DM was associated with an increased risk of hospitalization from any cause and association with cardiovascular death, stroke death, and death from all causes (Table [5](#Tab5){ref-type="table"}).Table 5Effect of a history of Type 2 DM and other outcomes(N / %)NO T2DMT2DMORIC95%PBefore matching All-cause Hospitalization4638 (12.54)4001 (20.66)1.8161.7331.903\< 0.001 Cardiovascular hospitalization707 (15.24)667 (16.67)1.1120.9891.2510.071 AMI hospitalization432 (9.31)434 (10.85)1.1851.0271.3670.018 Stroke hospitalization280 (6.04)241 (6.02)0.9980.8321.1960.979 All -- cause death1077 (2.91)684 (3.53)1.2201.1061.347\< 0.001 Cardiovascular death168 (15.60)157 (22.95)1.6121.2552.069\< 0.001 AMI hospitalization94 (8.73)98 (14.33)1.7491.2792.390\< 0.001 Stroke hospitalization76 (7.06)62 (9.06)1.3130.9091.8900.127After matching All-cause hospitalization2443 (13.24)3865 (20.95)1.7361.6421.836\< 0.001 Cardiovascular hospitalization403 (16.5)650 (16.82)1.0230.8911.1750.739 AMI hospitalization254 (10.4)424 (10.97)1.0620.8981.2560.474 Stroke hospitalization153 (6.26)234 (6.05)0.9650.7781.1990.737 All-cause death500 (2.71)676 (3.66)1.3651.2121.538\< 0.001 Cardiovascular death82 (16.4)156 (23.08)1.5291.1262.0850.005 AMI hospitalization46 (9.20)98 (14.5)1.6731.1402.4830.006 Stroke hospitalization38 (7.6)61 (9.02)1.2060.7761.8930.385

Discussion {#Sec13}
==========

The data from the *Framingham Heart Study* made it possible to identify DM as an important cardiovascular risk factor, mainly in women \[[@CR17]\]. To the best of our knowledge, this is the first report of an association between Type 2 DM and first cardiovascular events in a propensity-matched cohort of poor population without a history of previous cardiovascular events in Latin America and Colombia. According to several studies, all patients with DM can be treated as if they had prior cardiovascular disease since the risk of fatal AMI in patients with DM without previous AMI is similar to that of patients without DM who have survived an AMI \[[@CR11], [@CR17]\]. In the study of Becker et al., 10-year follow-up, women with DM, but without prior cardiovascular disease have a risk of cardiovascular events that is similar to that of women without diabetes but with prior cardiovascular disease, whereas in men the presence of prior cardiovascular disease conferred a higher risk \[[@CR11]\]. In our study, in the pre-matched cohort, the risk of the first cardiovascular event was significantly higher in women with Type 2 DM. In the post-matched cohort, these differences by sex disappeared for almost all outcomes, except for the stroke incidence that was significantly higher in women with Type 2 DM. In the *Framingham Heart Study* for stroke, women with DM had a higher incidence than men did with DM \[[@CR17]\].

The findings of the current analysis demonstrate that in patients without a personal history of previous cardiovascular events, a history of Type 2 DM was associated with an increased risk of a first cardiovascular event, which was primarily driven by an increase in AMI. Type 2 DM was also associated with risk of all-cause hospitalization, cardiovascular death, stroke death and all-cause death, but had no independent association with cardiovascular hospitalization. In the *Framingham Heart Study,* an increased mortality due to CVD in patients with DM compared with patients without DM was reported \[[@CR17]\]. In the INTERHEART study, a significant association between DM and AMI (OR 2.59, 95% CI 2.09--3.22) and a population risk attributable to DM of 17.2% was reported \[[@CR12]\]. In the INTERSTROKE study, a significant association between DM and stroke (RR 1.36, 95% CI 1.10--1.68) and a population risk attributable to DM of 5% was reported \[[@CR13]\]. These results should be interpreted considering the limitations and possible biases of a case-control study, in which the presence of exposure variables is determined after the onset of the disease \[[@CR18]\]. In randomized clinical trials such as the NAVIGATOR study, Latin American participants with glucose intolerance had an increased risk of cardiovascular death (HR 2.68, 95% CI 1.82--3.96) and composite cardiovascular outcome (HR 1.48, 95% CI 1.15--1.92). When the data are recorded in the context of a clinical trial, they may not reflect the real characteristics of the population by the specified selection criteria \[[@CR14]\]. In the PURE study identified that although risk-factor burden may be lower in LMIC, the risk of cardiovascular events was much higher \[[@CR19]\]. In the current study, the risk of first cardiovascular event was significantly higher in the Type 2 DM group (HR 1.69; 95% CI 1.43--2.00).

In Colombia, DM is among the first 10 causes of general mortality and within the first 20 causes of years of healthy life lost (YHLL) in a population ≥ 45 years \[[@CR10]\]. In Colombia, according to data from individual health care records (RIPS) and systematic reviews between 2010 and 2014, approximately 1,500,000 patients with type 2 DM were estimated \[[@CR10]\]. According to the National Department of Statistics (DANE) of Colombia, between January 2016 and August 2018, 60,944 deaths from ischemic heart disease (17.1%), 24,548 deaths from cerebrovascular diseases (6.9%) and 11,743 deaths from DM (3.3%), were estimated. According to the cumulative incidence of first cardiovascular events (3.5%) and cardiovascular mortality (22.9%) in Type 2 DM group (+) estimated in the current study, approximately 52,500 first-time cardiovascular events and around 12,000 cardiovascular deaths per year would be expected to occur. These estimates are similar to the annual deaths due to DM estimated by the International Diabetes Federation (IDF) (11,400 deaths due to DM) \[[@CR6]\] and the non-fetal death statistics of the DANE of Colombia (11,743 deaths due to DM).

Care of a patient with DM requires a multifactorial approach from the cardiovascular risk management program. All patients are at risk of developing vascular complications of DM, and these risks represents ultimately result in a doubled risk of mortality in patients with DM. Above and beyond targeted interventions, we now know that strict multifactorial interventions can result in a clinically significant reduction in both mortality and cardiovascular disease. These conclusions provide significant information on the importance of Type 2 DM in increasing the risk of first cardiovascular events in the poor population of the Colombian Caribbean region and the importance of an adequate diagnosis and treatment of Type 2 DM. However, evidence that an adequate metabolic control reduces the rates of cardiovascular events and death is not clear, although a discrete cardiovascular benefit may be observed after a prolonged follow-up period \[[@CR20]--[@CR24]\]. Evidence from HICs indicates that multiple risk factor intervention programmes do not result in reductions in cardiovascular events but may be effective in reducing mortality in high-risk hypertensive and diabetic populations. Due to the differences in the structure of the communities and the target population, caution is needed to generalize the results to LMICs. In the systematic review of Uthman et al., evidence about effectiveness of multiple risk factor interventions (with or without pharmacological treatment) in LMICs was scarce and only one study reported cardiovascular outcomes and multiple risk factor interventions did not reduce the incidence of cardiovascular events and none of the included trials reported all-cause mortality \[[@CR25]\]. For cardiovascular risk management programs it is important to evaluate the impact of their interventions over time to achieve optimal primary cardiovascular prevention in patients under the care of the program \[[@CR26]\]. There may be variation in the management plans of cardiovascular risk programs even within a given region beyond differences in health budget and system characteristics \[[@CR27]\]. The use of statins in the LMIC is low in comparison with the HIC \[[@CR28]\]. In the NAVIGATOR study, was reported that patients in Latin America used fewer therapies for prevention of cardiovascular events, such as aspirin (32% versus 47% in North America and 35% in Europe), lipid-lowering therapies (28% versus 55% in North America and 35% in Europe), and ACEIs (4% versus 9% in North America and 8% in Europe) \[[@CR14]\]. In the TECOS study, low use of statins and aspirin in Latin America compared to North America was reported \[[@CR29]\]. Recently, trials evaluating anti-diabetic drugs (empagliflozin, liraglutide, pioglitazone and semaglutide) have shown improved cardiovascular outcomes in patients with Type 2 DM \[[@CR30]--[@CR34]\]. The findings of the current analysis report a low use of statins, aspirin and new anti-diabetic drugs.

Our study has several strengths and limitations. More than 35 thousand of patients were included and, in spite of the nearly 1000 patients with type 2 DM lost, there were no differences in the incidences and incidence rates between the groups after propensity matching. We tried that the possibility of residual confounding, by the measured covariates and confounding by the unmeasured covariates that explain the associations between Type 2 DM and first cardiovascular event, were unlikely, considering that our patients were matched in 22 baseline characteristics and the conclusions of our analysis of sensitivity suggest that the association between Type 2 DM and a first cardiovascular event was quite insensitive to an unmeasured binary confounder.

Within limitations, we faced restrictions to access to sociodemographic data due to restrictions from the insurance company. In order to identify the diagnosis of cardiovascular outcomes we used the records of previous cardiovascular events and the ICD-10 hospital discharge code. However, we could not have data on confirmatory tests.

On the other hand, the exact date of death of patients and date of enrollment on the cardiovascular risk management program was not available.

We did not have access to information related to the treatment of cardiovascular events such as medications, thrombolysis, percutaneous coronary intervention (PCI), coronary artery bypass surgery (CABG), etc. In conclusion, in the poor population of the Colombian Caribbean without a personal history of cardiovascular events receiving standard therapy, DM produces cardiovascular outcomes. It is not known if a more aggressive screening of DM, DM education at every level, quality care registries and taxes on sugary drinks can reduce the risk of a first cardiovascular event in these patients and should be determined prospectively in future studies in Latin America.

AMI

:   Acute myocardial infarction

CVD

:   Cardiovascular disease

DANE

:   Department of Statistics of Colombia

HICs

:   High-income countries

ICD-10

:   International statistical classification of diseases and related health problems version 10

LMICs

:   Low- And Middle-Income Countries

NCDs

:   Noncommunicable diseases

T2DM

:   Type 2 diabetes millitus

YHLL

:   Years of healthy life lost
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